🇯🇵 Retevmo in Japan

PMDA authorised Retevmo on 27 September 2021

Marketing authorisation

PMDA — authorised 27 September 2021

  • Marketing authorisation holder: ELI LILLY JAPAN K.K.
  • Status: approved

Retevmo in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in Japan

Frequently asked questions

Is Retevmo approved in Japan?

Yes. PMDA authorised it on 27 September 2021.

Who is the marketing authorisation holder for Retevmo in Japan?

ELI LILLY JAPAN K.K. holds the Japanese marketing authorisation.